Cycloset vs. Metformin hydrochloride; repaglinide: side effect and effectiveness comparison - a phase IV clinical study
We compare the side effects and drug effectiveness of Cycloset and Metformin hydrochloride; repaglinide. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 4,514 people who take Cycloset and Metformin hydrochloride; repaglinide, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
4,514 people who take Cycloset and Metformin hydrochloride; repaglinide are studied.
What is Cycloset?
Cycloset has active ingredients of bromocriptine mesylate. It is often used in type 2 diabetes. eHealthMe is studying from 129 Cycloset users for its effectiveness, alternative drugs and more.
What is Metformin hydrochloride; repaglinide?
Metformin hydrochloride; repaglinide has active ingredients of metformin hydrochloride; repaglinide. It is often used in diabetes. eHealthMe is studying from 73 Metformin hydrochloride; repaglinide users for its effectiveness, alternative drugs and more.
Number of reports submitted per year:
Drugs being compared in this study:
- Cycloset (bromocriptine mesylate)
- Metformin Hydrochloride; Repaglinide (metformin hydrochloride; repaglinide)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
- not at all: 4.05 %
- somewhat: 9.46 %
- moderate: 29.73 %
- high: 32.43 %
- very high: 24.32 %
Metformin Hydrochloride; Repaglinide:
- not at all: 5.26 %
- somewhat: 14.04 %
- moderate: 43.86 %
- high: 26.32 %
- very high: 10.53 %
Want to compare Cycloset with Metformin hydrochloride; repaglinide?Personalize this study to your gender and age (0-99+).
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Alternative drugs to, pros and cons of:
How the study uses the data?
The study is based on bromocriptine mesylate and metformin hydrochloride; repaglinide (the active ingredients of Cycloset and Metformin hydrochloride; repaglinide, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.